Thymopentin methyl ester conjugate and preparation method thereof

A technology of peptide methyl esters and conjugates, which is applied in the field of precise structure drug modifiers-thymopentin methyl ester conjugates and its preparation, can solve the problems of increased polymer-drug conjugates and other problems, and achieve the extension of metabolic half-life, Avoid enzymatic hydrolysis and overcome the effect of easy ionization

Inactive Publication Date: 2017-02-01
SHANDONG BOCHUANG BIOTECHNOLOGY CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This shortcoming adds a lot of hidden dangers to the research and development of polymer-drug conjugates

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Chemical Synthesis of Intermediate Z-FPSDM-Arg(Pbf)-Lys(BOC)-OH

[0037] Z-FPSDM-Arg(Pbf)-Lys(BOC)-OMe was dissolved in MeOH (18ml), and LiOH aqueous solution (1.0M, 2.0ml) was added with stirring. The reaction solution was stirred at room temperature for 3 h until TLC showed that the reaction was complete. The solvent was pumped out under reduced pressure at 30°C, the residue was dissolved in DCM (60ml), and then washed with HCl solution (0.2M, 2×20ml) and saturated brine (2×20ml) successively, anhydrous Na 2 SO 4 After drying, the solvent was removed under reduced pressure at 30°C, and the resulting residue was washed with DCM / Et 2 O / Haxane (1:6:1) recrystallized to obtain the target product Z-FPSDM-Arg(Pbf)-Lys(BOC)-OH(MF.C 66 h 108 N 10 o 20 S, MW.1393.70).

Embodiment 2

[0039] Chemical Synthesis of FPSDM-TP-5 Derivatives

[0040] Z-FPSDM-Arg(Pbf)-Lys(BOC)-OH 197.6mg(MF.C 66 h 108 N 10 o 20 S, MW.1393.70, 0.142mmol) and HOCt 89.2mg (0.568mmol, 4eq) were dissolved in anhydrous DCM (10ml), and DIC 26μl (0.17mmol, 1.2eq) was added under stirring, and after stirring at room temperature for 1h, dropwise To the tripeptide derivative H-Asp(OtBu)-Val-Tyr-OMe0.066g (C 23 h 35 N 3 o 7 , MW.465.55, 0.142mmol) in DCM (8ml) solution, DIEA 0.10ml was added at the same time, stirred at room temperature for 8h until TLC showed that the reaction was complete. DCM (50ml) was added to the reaction solution, followed by HCl (0.2M, 2 × 20ml), H 2 O (20ml), NaOH (0.2M, 2×20ml) and saturated NaCl solution (2×20ml) were washed, then washed with Na 2 SO 4 Dry, and remove the solvent under reduced pressure at 30°C to obtain 0.188g of the crude product of the coupled compound Z-FPSDM-Arg(Pbf)-Lys(BOC)-Asp(OtBu)-Val-Tyr-OMe(MF.C 89 h 141 N 13 o 26 S, MW.184...

Embodiment 3

[0042] Synthesis of Boc-protected dipeptide derivatives

[0043] Boc-Val-OH (1-2, MW.217.27, 1.0864g, 5.0mmol) and HOCt (MF.C 5 h 7 N 3 o 3 , MW.157.12, 0.9427g, 6.0mmol, 1.2eq) was dissolved in anhydrous DCM (4.0ml), and DIC (MF.C 7 h 14 N 2 , MW.126.20, d.0.839, 0.91ml, 6.0mmol, 1.2eq) in the above solution. Suspend H-Tyr-OMe·HCl (1-1, MW.231.68, 1.1584g, 5.0mmol) in DCM (5.0ml), add DIEA (MF.C 8 h 19 N, MW.129.24, d.0.728, 1.95ml, 11.0mmol, 2.2eq), then the mixed solution of 1-2 / HOCt / DIC / DCM was added dropwise thereto, stirred at room temperature for 2h, and TLC detected that the reaction was complete. The reaction solution was filtered with NaHCO 3 (0.2M, 2×25ml), hydrochloric acid (0.2M, 2×20ml) and saturated brine (30ml) were extracted sequentially, anhydrous Na 2 SO 4 After drying and concentrating under reduced pressure, a light yellow oil was obtained, which was added with Et 2 O has urea precipitation, filter it quickly, add an appropriate amount of Et 2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a thymopentin methyl ester conjugate and a preparation method thereof. The preparation method specifically comprises the following steps: dissolving Z-FPSDM-Arg(Pbf)-Lys(BOC)-OH and 1-hydroxybenzotriazole (HOBt) / DCC / MMF in anhydrous trichloromethane, adding N,N-ethyldiisopropylamine and other specific solvents for reacting while stirring, thereby obtaining an active ester A; dripping the active ester into an alkaline solution of tripeptide derivatives, adding N,N-diisopropylamine and other specific solvents, thereby obtaining a coarse product of the thymopentin methyl ester conjugate; and finally, performing deprotection, reduced pressure distillation, washing and drying, thereby obtaining an accurately modified thymopentin methyl ester conjugate. The preparation method disclosed by the invention is fewer in byproducts and high in synthetic efficiency. The thymopentin methyl ester conjugate has the effects of maintaining the biological activity of TP-5, relieving or avoiding enzymolysis of TP-5 and further obviously prolonging the in-vivo metabolic half-life, and is extremely high in clinical application value.

Description

technical field [0001] The invention relates to a thymopentin methyl ester conjugate and a preparation method thereof, in particular to a drug modifier with a fixed molecular weight and precise structure-thymopentin methyl ester conjugate and a preparation method thereof. And this method is suitable for large-scale production. Background technique [0002] Thymopentin (Thymopetidu, TP-5) is a pentapeptide fragment of the active center of the endogenous polypeptide Thymopoietin. Bi-directional regulation, is a clinically important immune balance regulator. TP-5 can be used for anti-tumor adjuvant drugs, hepatitis B, autoimmune diseases, senile and frail immune function; it can also be used as an adjuvant drug in combination with many commonly used drugs to enhance the efficacy, including interferon, hormones, analgesia Drugs, antihypertensive drugs, cardiovascular disease drugs, central nervous system drugs, etc. [0003] TP-5 is extremely unstable in the body and is easil...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/66C07K1/04
CPCC07K14/66
Inventor 高秀伟
Owner SHANDONG BOCHUANG BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products